Key Metrics
CiteScore 

56.9
Eigenfactor 

0.1 - 0.5
H-Index 

382
Impact Factor 

>= 25
Scite Index 

0.86 5-Year SI

SJR 

Q1Oncology

SNIP 

11.42
Recommended pre-submission checks
Powered by 

Topics Covered on The Lancet Oncology
The Lancet Oncology Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in The Lancet Oncology
European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.
- 1 Jul 2026
- The Lancet. Oncology
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
- 1 Jul 2026
- The Lancet. Oncology
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
- 1 Jul 2026
- The Lancet. Oncology
Delivering transformational change for patients and the environment through England's National Cancer Plan.
- 1 Jul 2026
- The Lancet. Oncology
Preliminary results from PRIMARY2: bringing colour to a grey arena.
- 1 Jul 2026
- The Lancet. Oncology
Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
- 1 Jul 2026
- The Lancet. Oncology
European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.
- 1 Jul 2026
- The Lancet. Oncology
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
- 1 Jul 2026
- The Lancet. Oncology
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
- 1 Jul 2026
- The Lancet. Oncology
Delivering transformational change for patients and the environment through England's National Cancer Plan.
- 1 Jul 2026
- The Lancet. Oncology
Preliminary results from PRIMARY2: bringing colour to a grey arena.
- 1 Jul 2026
- The Lancet. Oncology
Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
- 1 Jul 2026
- The Lancet. Oncology